Annuncio pubblicitario
Italia markets close in 7 hours 15 minutes

  • FTSE MIB

    34.130,56
    +190,81 (+0,56%)
     

  • Dow Jones

    38.085,80
    -375,12 (-0,98%)
     

  • Nasdaq

    15.611,76
    -100,99 (-0,64%)
     

  • Nikkei 225

    37.934,76
    +306,28 (+0,81%)
     

  • Petrolio

    84,04
    +0,47 (+0,56%)
     

  • Bitcoin EUR

    59.958,91
    +303,57 (+0,51%)
     

  • CMC Crypto 200

    1.387,77
    -8,76 (-0,63%)
     

  • Oro

    2.358,60
    +16,10 (+0,69%)
     

  • EUR/USD

    1,0743
    +0,0010 (+0,10%)
     

  • S&P 500

    5.048,42
    -23,21 (-0,46%)
     

  • HANG SENG

    17.675,82
    +391,28 (+2,26%)
     

  • Euro Stoxx 50

    4.969,36
    +30,35 (+0,61%)
     

  • EUR/GBP

    0,8577
    +0,0003 (+0,03%)
     

  • EUR/CHF

    0,9784
    -0,0001 (-0,01%)
     

  • EUR/CAD

    1,4652
    +0,0003 (+0,02%)
     

Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Madrigal Pharmaceuticals, Inc.
·1 minuto per la lettura
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.

CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 9:30 am ET.

The fireside chat will be webcast and an archived recording will be available for replay in the Investors & Media section of the Madrigal website following the event.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in four Phase 3 clinical studies (MAESTRO-NASH, MAESTRO-NAFLD-1, MAESTRO-NAFLD-OLE and MAESTRO-NASH Outcomes) designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com